The emergency use authorization for REGEN-COV (a combination of two monoclonal 
antibodies, casirivimab and imdevimab) has been revised to include postexposure 
prophylaxis of COVID-19 in adults and children 12 years of age and older who, if 
they become COVID-19 positive, are at high risk for severe disease.Prophylaxis 
with REGEN-COV is not a substitute for vaccination against COVID-19.